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ABSTRACT
Follicular dendritic cell (FDC)-sarcoma is a rare neoplasm with morphologic and 
phenotypic features of FDCs. It shows an extremely heterogeneous morphology, 
therefore, its diagnosis relys on the phenotype of tumor cells. Aim of the present 
study was the identification of new specific markers for FDC-sarcoma by whole 
transcriptome sequencing (WTS). Candidate markers were selected based on gene 
expression level and biological function. Immunohistochemistry was performed on 
reactive tonsils, on 22 cases of FDC-sarcomas and 214 control cases including 114 
carcinomas, 87 soft tissue tumors, 5 melanomas, 5 thymomas and 3 interdigitating 
dendritic cell sarcomas. FDC secreted protein (FDCSP) and Serglycin (SRGN) proved 
to be specific markers of FDC and related tumor. They showed better specificity and 
sensitivity values than some well known markers used in FDC sarcoma diagnosis 
(specificity: 98.6%, and 100%, respectively; sensitivity: 72.73% and 68.18%, 
respectively). In our cohorts CXCL13, CD21, CD35, FDCSP and SRGN were the best 
markers for FDC-sarcoma diagnosis and could discriminate 21/22 FDC sarcomas from 
other mesenchymal tumors by linear discriminant analysis. In summary, by WTS 
we identified two novel FDC markers and by the analysis of a wide cohort of cases 
and controls we propose an efficient marker panel for the diagnosis of this rare and 
enigmatic tumor.
INTRODUCTION
Follicular dendritic cell sarcoma (FDC-S) is the 
neoplastic proliferation of follicular dendritic cells 
(FDC) [1–2]. FDC belong to the stromal compartment 
of secondary lymphoid organs [3] and share crucial 
interaction capacities with the haematopoietic counterpart; 
both quality and effectiveness of immune responses 
depend from their integrity [4–6]. Therefore, FDC-S is 
included in the WHO classification of Haematopoietic 
tumors [1] and not in the WHO classification of Tumors 
of Soft Tissue and Bone [7] despite of its mesenchymal 
Research Paper
Oncotarget16464www.impactjournals.com/oncotarget
origin. The complex mechanisms mediating these 
functions are still largely unknown but new insights have 
been recently achieved in experimental models [4, 8–10].
FDC-S occurs in adults (median age 50 years), 
with no gender predilection, in both nodal and extranodal 
sites [11–15]. Its behavior is unpredictable; in a 
recent large review study, local recurrence and distant 
metastasis were reported to be equal to 28.1% and 
27.2%, respectively [12].
On histology, FDC-S is characterized by extreme 
variability in cell composition and growth patterns, 
diagnosis is supported by the use of a panel of FDC-
associated immunohistochemical markers combined 
with others, specific for epithelial neoplasms, soft tissue 
tumors and melanoma, to be used for exclusion [16]. 
Some differential diagnoses can be extremely challenging, 
particularly those entities typically prone to antigen loss (i.e. 
melanomas and undifferentiated carcinomas) the markers of 
which may be occasionally expressed by FDC-S (i.e. S100 
and EMA) [16].
At present, the most widely used FDC-S markers 
are complement component receptor (CR) 1 (CD35), CR2 
(CD21), Fc fragment of IgE receptor 2 (FCER2, CD23) and 
Clusterin. Recently, other proteins were identified including 
CXCL13 [17], D2-40 [18] and Claudin 4 [19]. Noteworthy, 
FDC-S frequently express a defective phenotype which 
may lead to misdiagnosis [12]. 
The molecular pathogenesis of FDC-S is largely 
unknown. Epidermal growth factor receptor signaling is 
known to support FDC-S proliferation [20-21]; mutations 
affecting the nuclear factor κ B pathway and cell cycle 
regulation were recently identified, by targeted next generation 
sequencing, in a subgroup of FDC-S [22]. Data on whole 
genome and whole transcriptome sequencing on this tumor 
are still lacking.
In order to explore the molecular and proteomic 
landscape of FDC-S we performed the first whole 
transcriptome sequencing analysis on two FDC-S cases. 
Pathway enrichment analysis was performed and new 
candidate immunohistochemical markers were identified 
and validated in a large cohort of FDC-S and controls.
RESULTS
Pathological features of FDC-S undergoing 
whole transcriptome sequencing
The clinical, morphological and phenotypical data 
of the two cases of FDC-S used for WTS are detailed in 
Table 1 and shown in Figure 1.
The mediastinal biopsy of Case #1 showed highly 
pleomorphic cells, often multinucleated; with nuclear 
pseudo-inclusions and atypical mitoses. Reactive T and, 
less numerous, B- lymphocytes were intermingled within 
the tumor. Differently, in Case #2, tumor cells were 
bland looking, spindle, arranged in parallel fascicles; 
mitoses were few and never atypical, scattered mature 
lymphocytes were present. Tumor cell content was 
estimated on histological section to be above 40% in 
both cases. Their phenotype (reported in Table 1) showed 
expression of at least two FDC-specific markers.
Whole transcriptome of FDC-S
No fusion transcripts were detected by whole 
transcriptome sequencing excluding the presence of 
chromosome translocations with oncogenic significance.
Genes with reads per kilobase per million mapped 
reads (RPKM) higher than 1 were 17,956 in case #1 
and 18,118 in case #2. IGK (RPKM = 32,171.7754) and 
FDCSP (RPKM = 11,593.3535) had the highest expression 
value, in case #1 and #2, respectively.
Gene ontology and functional annotation of both lists 
generated an equivalent output, despite the differences in 
tissue type and tumor morphology.
Annotation of gene list for biological processes 
suggested a metabolically active tumor given enrichment of 
“metabolic process” (GO:0008152) and “cellular process” 
(GO: 0009987). Among the cellular components actin-
related cytoskeleton (GO: 0015629) resulted enriched, 
in line with the actin-dependent activity of FDC [23]. 
Overrepresentation analysis was performed with the 
Panther pathway annotation dataset separately, in the two 
cases. Among others, a statistically significant (p < 0.05) 
overrepresentation of “Ubiquitin Proteasome” (P00060) 
pathway was detected in both cases, in line with the recent 
evidence of NFκB pathway regulatory-factors loss of 
function in this tumor [22]. According to the histological 
evidence of a higher T-cell infiltrate, “T-cell activation” 
(P00053) was increased in the transcriptome of case #1 
while “Integrin Signalling” (P00034) and “Epidermal 
growth factor receptor (EGFR) signalling” pathway 
(P00018) were overrepresented in case #2, consistent with 
previous observations of activated EGFR signalling in 
FDC-S. [20–21]. Fold changes and p-values are listed in 
Supplemental material, Supplementary Table 1.
Transcripts coding for established 
immunohistochemical FDC-S markers are 
among the top 10% of FDC-S transcriptome
Genes coding for FDC markers showed expression 
values higher than 55 RPKM and were among the “top 10%” 
genes of each transcriptome. Notably, CLU and CXCL13 
were those with the highest RPKM; CLU had the second 
transcription value in both; CXCL13 was respectively at the 
7th and 36th position (Supplementary Table 2). Accordingly, 
the transcriptome of the CD21-negative case #1 showed 
low expression values of the CD21-coding gene CR2 and 
CR1, gene coding for CD35, had low RPKM values in both 
transcriptomes, in line with the negativity of both cases for 
this protein by immunohistochemistry (Table 1, Figure 1).
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FDCSP and SRGN have high expression values 
in FDC-S and are expressed by normal FDC
To identify additional markers for FDC-S we 
selected gene products with biological functions related to 
the germinal center reaction among the top 10% transcripts 
of both tumors.
Follicular dendritic cell secreted protein (FDCSP), 
also known as Chromosome 4 open reading frame 
7(C4Orf7) and Serglycin (SRGN) were selected and 
antibodies against their proteins were tested on reactive 
tonsils. The cytoplasm of normal FDC, mostly located in 
the light zone of germinal centers of secondary lymphoid 
follicles, stained positive for both proteins with a 
perinuclear pattern (Figure 2A and 2B).
FDCSP and SRGN exhibit good sensitivity and 
specificity for FDC-S diagnosis
Immunohistochemistry on follicular dendritic cell 
sarcomas for FDCSP was positive in sixteen cases (16/22, 
72.73%) with either an intense and diffuse cytoplasmic 
staining or a prevailing perinuclear positivity. Reaction for 
SRGN was detected in fifteen cases (15/22, 68.18%) and, 
similarly to CXCL13, displayed a strong Golgi staining 
pattern with or without diffuse cytoplasmic reaction; 
notably, nuclear pseudo inclusions were frequently SRGN-
positive (Figure 2).
In order to test the specificity of FDCSP and SRGN 
in FDC-S diagnosis we stained 87 soft tissue tumors, 
5 thymomas, 5 melanomas (Supplementary Table 3), 3 
interdigitating dendritic cell sarcomas and 114 carcinomas 
[24]. FDCSP was expressed by two soft tissue tumors, one 
sinonasal haemangiopericytoma (SNHP-1) and one synovial 
sarcoma (SS-2); SRGN was negative in all (Supplementary 
Table 4). Notably, one case of interdigitating dendritic cell 
sarcoma expressed FDCSP in about 40% of neoplastic cells 
while it was negative for SRGN and other FDC markers. 
No reactivity for FDCSP and SRGN was detected on 
melanomas, thymomas or carcinomas.
CXCL13, CD21, CD35, FDCSP and SRGN are 
the best marker combination in FDC-S diagnosis
In order to compared the performance of FDCSP 
and SRGN with known FDC-S markers in the differential 
with soft tissue tumors, we tested CD21, CD23, CD35, 
CXCL13, Clusterin, Claudin 4 and Podoplanin in our 
groups of tumors and controls.
CXCL13, CD21 and Clusterin were the most 
retained markers in FDC-S with sensitivities of 90.91% for 
the first and 81.82% for the latter two (Table 2). CD35 and 
FDCSP were both expressed by 72.73% (16/22) of cases. 
The least sensitive were CD23 and Podoplanin, positive 
in 63.64% (14/22) of cases and Claudin 4, retained only 
by half of FDC-S (10/20). The highest specificity was 
observed for SRGN, CXCL13 and for complement and Fc 
receptors (CD21, CD35 and CD23): they were negative in 
all soft tissue tumors used as controls. Adversely, Clusterin 
showed a diffuse, undoubtful, expression in six cases of 
Table 1: Clinical, phenotypical and molecular data of FDC-S submitted for whole transcriptome 
sequencing
Case #1 Case #2
Gender F M
Age (years) 71 76
Site Mediastinum Soft tissues of the thigh
Maximum diameter 5.9 cm NA
Therapy and follow up Surgery and radiotherapy 
NED (15 months)
NA
FDC-S markers
GENE_Protein
protein 
expression  
by IHC
gene 
transcript 
(RPKM)
protein 
expression  
by IHC
gene transcript (RPKM)
CR2_CD21
FCER2_CD23
CR1_CD35
CLU_Clusterin
PDPN_Podoplanin
CXCL13_CXCL13
–
+
–
+
+
+
49.0621
3519.927
15.26415
10482.2246
213.73975
8698.03906
+
+
–
+
+
+
940.95374
295.29196
54.7856
7388.229
103.46978
1487.44849
Expression values of the genes encoding for CD21, CD23, CXCL13, CD35, Clusterin and Podoplanin correlate with 
immunohistochemical expression of their protein.
F, female; FDC-S, follicular dendritic cell sarcoma; IHC, immunohistochemistry; M, male; NA, not available; NED, no 
evidence of disease; RPKM, kilobase per million mapped reads.
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GIST (6/20, 30% not shown), all from extra-gastric sites. 
Podoplanin was expressed by two thirds of IMT cases (4/6, 
66.67%, not shown), 25% (3/12) of SS, 15% (3/20) of 
GIST and 10.53% of SFT (2/19). Claudin 4 was expressed 
in one case of SS and one case of ALK-negative IMT.
Sensitivity and specificity of each marker were 
plotted on a ROC curve and the value of their area under 
the curve (AUC) was calculated (Figure 3, Table 2).
Notably, CXCL13 showed the highest AUC, 
representing the marker with the best performance in 
Figure 1: Morphology and phenotype of FDC-S cases submitted for transcriptome sequencing. In Case #1 (A, C, E and G) 
atypical cells were epithelioid, pleomorphic, intermingled by numerous, small lymphocytes (A, hematoxylin and eosin), they stained 
negative for CD21 (C) but intensely expressed Clusterin (E) and CXCL13 (G). Case #2 (B, D, F and H) showed a different morphology 
with spindle atypical cells, arranged in fascicles (B, hematoxylin and eosin), positive for CD21 (D), Clusterin (F) and CXCL13 (H), the 
latter with a punctuate Golgi dot pattern. Magnification: 200×.
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Table 2: Sensitivity, specificity, area under the curve (AUC) and significance p-value of FDC 
markers
Marker Sensitivity(+/FDC-S)
Specificity
(–/STT) AUC p-value
CXCL13 90.91% (20/22) 100.00% (72/72) 0.955 < 0.0001
CD21 81.82% (18/22) 100.00% (72/72) 0.909 < 0.0001
CD35 72.73% (16/22) 100.00% (72/72) 0.864 < 0.0001
FDCSP 72.73% (16/22) 97.20% (70/72) 0.850 < 0.0001
SRGN 68.18% (15/22) 100.00% (72/72) 0.841 < 0.0001
Clusterin 81.82% (18/22) 81.94% (59/72) 0.810 < 0.0001
CD23 63.64% (14/22) 100.00% (72/72) 0.800 < 0.0001
Podoplanin 63.64% (14/22) 83.33% (60/72) 0.767 < 0.0001
Claudin4 50.00% (10/20) 98.61% (71/72) 0.736 < 0.0001
Figure 2: Expression patterns of FDCSP and SRGN on normal and neoplastic FDC. In the contest of reactive germinal 
centers normal FDC react for both FDCSP and SRGN protein with a perinuclear expression pattern (A, B). FDCSP (C, E) and SRGN 
(D, F) are axpressed also in the cytoplasm of neoplastic FDC either with diffuse and intense staining or with a more delicate punctuate, 
cytoplasmic dot. SRGN often stained nuclear pseudo-inclusions (F, inset). Magnification: (A and B) 400×. (C, D, E and G) 200×. Insets: 
600×. Abbreviations: FDC-S, follicular dendritic cell sarcoma; FDCSP, FDC secreted protein; SRGN, Serglycin.
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the differential diagnosis of FDC-S with other tumors of 
mesenchymal origin. It was followed, in order, by CD21, 
CD35, FDCSP and SRGN (Figure 3A). Other widely used 
FDC-S markers such as Clusterin, CD23 and Podoplanin 
showed a lower AUC value (Figure 3B).
Evaluating the power of the combination of 
CXCL13, CD21, CD35, FDCSP and SRGN, by linear 
discriminant analysis (LDA), this marker combination 
showed a correct classification for 98.94% (93/94) of the 
cases tested, representing the best marker combination for 
the identification of FDC-S. When considering the same 
set of markers, FDC-S cases were nicely discriminated 
from the controls by principal component analysis 
(Supplementary Figure 1) with the exception of one 
case, FDC-S-18, by LDA (Figure 3C). The latter case 
developed as a retroperitoneal mass in a 73 years-old 
woman; neoplastic cells stained for Clusterin, Podoplanin 
and SRGN but were negative for all the other markers and 
may therefore represent an exceptional case.
DISCUSSION
Follicular dendritic cell sarcoma (FDC-S) is a 
mesenchymal tumor with morphological and phenotypical 
features of follicular dendritic cells [1, 4, 12, 16]. FDC-S 
have been reported in numerous sites of the body, both 
nodal and extranodal [12]. The morphological appearance 
of FDC-S includes different growth patterns: fascicular, 
Figure 3: Representation of sensitivity and specificity of FDC markers by ROC curves and hierarchical clustering. 
The graphs represent the AUC of FDC markers: those with best sensitivity and specificity values, CXCL13, CD21, CD23, FDCSP and 
SRGN are plotted in (A) Clusterin, Podoplanin, CD23 and Claudin 4 are displayed in (B). Hierarchical clustering performed considering 
IHC expression scores of the five markers CXCL13, CD21, CD23, FDCSP and SRGN in 22 FDC-S and 72 soft tissue tumors show a neat 
separation of FDC-S from controls with the exception of a single FDC-S case (C). Abbreviations: DF, desmoid type fibromatosis; DFSP, 
dermatofibrosarcoma protuberans; FDC-S, follicular dendritic cell sarcoma; GIST gastrointestinal stromal tumor; IMT, inflammatory 
myofibroblastic tumor; LGF, low grade fibromyxoid sarcoma; SFT, solitary fibrous tumor; SNHP, sinonasal haemangiopericytoma; SS, 
synovial sarcoma.
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storiform, whorled or diffuse; puzzle-like, nodular (i.e. 
folliculocentric) and angiomatoid architectures have also 
been described [1, 25]. Neoplastic FDC are spindle, oval 
or epithelioid and often show the same characteristics of 
normal FDC but nuclear pleomorphism may also occur [1]. 
Given its heterogeneous morphology, FDC-S diagnosis is 
supported by the use of immunohistochemistry, it demands 
the usage of a wide panel of antibodies, given its frequent 
loss of specific antigens and the possibility of focal 
reactivity for epithelial markers [16–17]. FDC-S in both 
nodal and extranodal sites may mimic a wide spectrum 
of neoplasms including metastatic melanomas, poorly 
differentiated carcinomas, both epithelioid and spindle 
cell sarcomas. The use of recently identified antibodies, 
such as STAT6 for solitary fibrous tumor and TLE1 for 
synovial sarcoma, are helpful in some settings. However, 
not all entities have highly specific and retained markers 
and a panel of antibodies must be applied, still.
We performed whole transcriptome sequencing 
(WTS) on two cases of FDC-S in order to explore the 
biology of this rare tumor in terms of gene fusions and 
gene expression.
Our study did not identify fusion transcripts in the 
two cases of FDC-S analyzed excluding the presence of 
chromosome translocations of oncogenic significance 
in these patients. However, we could use expression 
values obtained from WTS to identify two novel 
immunohistochemical markers for both normal and 
neoplastic FDC: Follicular dendritic cell secreted protein 
(FDCSP) and Serglycin (SRGN). 
FDCSP, isolated in 2002 from human reactive 
tonsils, is specifically expressed by B-cell-activating-
FDC [26]. The few studies performed to understand the 
functions of this protein suggest that it can modulate 
B-cell immune response [26–27] and may have a role in 
autoimmune diseases [28–29]. SRGN is an intracellular 
proteoglycan implicated in secretory granules formation 
and immune response modulation as demonstrated in 
knock-out mouse models [30–31]. SRGN expression 
was reported in the transcriptome of different cell types, 
including stromal and endothelial cells [30]. Notably, 
both markers were previously associated with metastasis 
and dismal prognosis in a wide range of carcinomas 
[31–36] but we could not detect their expression, by 
immunohistochemistry, in our cohort of controls.
In FDC-S diagnosis, FDCSP and SRGN showed both 
a good sensitivity, higher than CD23 and Claudin 4, and 
an extremely good specificity, evaluated on 214 controls 
including carcinomas, soft tissue tumors, melanomas, 
thymomas and interdigitating dendritic cell sarcomas. 
SRGN, together with CD21 and CD35, was negative in 
all non-FDC-S tumors; FDCSP, expressed by one case 
of SNHP, one case of SS and one case of interdigitating 
dendritic cell sarcoma, still showed a better performance 
than other widely used FDC markers. Clusterin, highly 
expressed at transcriptome level, is a highly sensitive 
marker for FDC-S [37–38]. However, in our study, it 
stained also 60% of GISTs occurring in the GI tract, outside 
stomach (e.g. ileum wall), suggesting to use it with caution 
(eventually together with CD117 and DOG1). Meanwhile, 
Podoplanin, a sensitive marker for FDC-S [18], was 
expressed in two thirds of IMT, in a fraction of GIST, SFT 
and SS. Pathologists should be aware of these potential 
pitfalls in the differential diagnosis of FDC-S occurring in 
extranodal sites and should consider applying also other 
newly, highly specific markers, such as STAT6 [39] and 
TLE1 [40], in support.
In our study the combination of CXCL13, 
CD21, CD35, FDCSP and SRGN reached a very good 
discriminatory power in distinguishing FDC-S from other 
soft tissue tumors. In particular, CXCL13, a chemokine 
ligand recently reported in FDC-S [17], was the marker with 
best sensitivity and specificity combination (Table 2). The 
usefulness of our five marker combination was confirmed 
by the good results obtained by linear discriminant analysis 
and the almost perfect separation in the hierarchical 
clustering profile where all FDC-S cases, but one, grouped 
together. Notably, all the correctly classified FDC-S cases 
were positive for at least two markers among CXCL13, 
CD21, CD35, FDCSP and SRGN; this information could 
be easily applicable in the routine diagnosis of this tumor.
FDC-S with a highly defective phenotype do 
exist and were present also in our set of cases, this 
could be related to a different grade of differentiation or 
“activation” of neoplastic FDCs and suggests to further 
explore the biology of these tumors in correlation with 
other mesenchymal tumors with the same, putative, cell 
of origin [9].
In conclusion, by a combined approach of 
next generation sequencing and high throughput 
immunohistochemistry we identified two novel markers for 
FDC-S, FDCSP and SRGN, and suggested a highly effective 
and ready-to-use approach for its differential diagnosis with 
other mesenchymal tumors.
MATERIALS AND METHODS
Case selection
Twenty-two cases of follicular dendritic cell sarcoma 
cases (FDC-S) were retrieved from the archives of 
pathology of the University Hospitals of Brescia, Frankfurt 
am Main, Bologna, Lisbon, Barcelona, Vienna and Mumbay. 
Diagnosis were confirmed at a multi head microscope by the 
authors (C.A., F.F, M.L.H., S.H. and S.A.P.).
Eighty-seven cases of soft tissue tumors were 
retrieved from the archives of the department of pathology 
of Spedali Civili di Brescia. They included 19 Solitary 
fibrous tumors (SFT, all STAT6-positive) and 4 Sinonasal 
haemangiopericytoma (SNHP, STAT6- negative [41]), 
20 gastrointestinal stromal tumors (GIST, DOG1 and/
or CD117-positive), 12 synovial sarcomas (SS, all 
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TLE1-positive, 9 with split of 18q11.2, evaluated by 
fluorescence in situ hybridization with SS18 probe), 6 
inflammatory myofibroblastic tumors (IMT, 4 ALK-
positive), 5 dermatofibrosarcomas protuberans (DFSP), 
5 leiomyosarcomas (LMS), 5 angiosarcomas (AS), 4 
desmoid-type fibromatosis (DTF), 3 undifferentiated 
pleomorphic sarcomas (UPS), 2 dedifferentiated 
liposarcomas (DLS) and 2 low-grade fibromyxoid sarcomas 
(LGFMS, all MUC4-positive). Cases were revised and 
diagnosis confirmed by expert soft tissue pathologists 
(Demographical data are detailed in Supplementary 
Table 3). Informed consent was obtained according to the 
Declaration of Helsinki and the local ethics committees 
agreed on the study.
RNA extraction from frozen material and whole 
transcriptome sequencing
Total ribonucleic acid (RNA) was extracted from 
the frozen tissue of four FDC-S (RNeasy Mini kit, Qiagen, 
Hilden, Germany). RNA integrity was evaluated by a 
Bioanalyzer (Agilent, Waldbronn, Germany) and two 
of the four cases showed sufficient quality for whole 
transcriptome sequencing (WTS). The latter was performed 
on an Illumina HiSeq platform (EMBL, Heidelberg, 
Germany) after library preparation with the SMARTer™ 
Ultra Low RNA Kit (Clontech, Mountain View, CA 
USA). The hg19 Genome Reference Consortium GRCh37 
was used as reference genome applying the Genomatix 
Software (Genomatix GmbH. Munich, Germany) using 
default parameters.
Biostatistical analysis
Transcriptome data were analyzed for fusion 
transcripts by Genomatix Mining Station and Genome 
Analyzer.
Gene expression values were normalized and ordered 
per kilobase per million mapped reads (RPKM). Genes with 
RPKM higher or equal to 1 underwent gene annotation 
analysis by Gene Ontology Consortium-annotations-
based Panther software (www.pantherdb.org) [42]; 
overrepresentation test (by bimodal test with Bonferroni 
correction) and enrichment test (by Mann-Whitney test) 
were performed on both Panther and Genomatix softwares. 
After immunohistochemical analysis, sensitivity, 
specificity and corresponding p-values were calculated for 
candidate and known FDC-S markers. Receiver Operating 
Characteristic (ROC) curve analysis was performed with 
the ©1993–2016 MedCalc Software using the methodology 
detailed in DeLong et al. [43] for calculation of the Standard 
Error and the exact Binomial Confidence Interval for the 
Area Under the Curve. Hierarchical clustering, principal 
component analysis (PCA) and linear discriminant analysis 
were performed with the PAST software [44].
Tissue microarray preparation and 
immunohistochemistry
Tissue microarray (TMA) blocks were created from 
FDC-S and 72 controls (control group #1, Supplementary 
Table 3), using an automated tissue microarray (TMA 
Master, 3DHistech, Budapest, Hungary). Three 
representative tumor cores (1 or 1.5 mm diameter) were 
identified on hematoxylin and eosin (H&E) stained 
sections and punched from the original tissue blocks. 
Immunohistochemistry for known and novel FDC 
markers was performed on these TMAs. In order to 
further confirm their specificity, FDCSP and SRGN were 
additionally applied on TMAs including 114 carcinomas of 
different origin, previously described [24], and on whole 
tissue sections of 28 additional control cases (control group 
#2, Supplementary Table 3). Antibodies applied are detailed 
in Supplementary Table 5.
Immunohistochemistry for FDCSP and SRGN 
was performed with automatic immunostainer (Dako, 
Glostrup, Denmark) or manually, showing equivalent 
results; immunohistochemistry on controls was performed 
automatically (Leica Biosystems, Wetzlar, Germany).
Stained sections were digitalized using the Aperio 
Scanscope System (Leica Biosystems) and evaluated by 
two pathologists (S.H. and L.L.). Cases were scored positive 
when reaction occurred on at least 30% of tumor cells.
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